#4-87E. Unveiling the Synergistic Storm: IL-17 and IFN-γ in Giant Cell Arteritis (Arthritis Rheumatol, 2026)

Where lie the new therapeutic targets for refractory giant cell arteritis (GCA)? This episode explores the paper "In Synergy With Interferon-γ, Interleukin-17 Activates Vascular Stromal Cells Toward a Proinflammatory Profile in Giant Cell Arteritis." This study investigated the role of IL-17 in GCA, revealing that IL-17 activates vascular myofibroblasts and acts synergistically with IFN-γ to promote the production of inflammatory mediators such as IL-6. Furthermore, it confirmed that the IL-17 inhibitor secukinumab effectively suppresses these inflammatory responses45. The most crucial finding suggests a novel mechanism wherein IL-17 directly targets vascular stromal cells to amplify inflammation, providing a strong biological rationale for the utility of IL-17 inhibitors in GCA. However, when critically appraising this paper, we must consider the limitation of using cells derived from non-GCA temporal artery biopsies as an in vitro model. Understanding this mechanism is vital for clinicians, as it highlights the potential of IL-17 inhibition as a promising new therapeutic option for challenging GCA cases, offering valuable insights for future clinical applications and improving daily patient care.

Citation: Greigert H, Samson M, et al. In Synergy With Interferon-γ, Interleukin-17 Activates Vascular Stromal Cells Toward a Proinflammatory Profile in Giant Cell Arteritis. Arthritis & Rheumatology. 2026. DOI: 10.1002/art.70051

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.